
BML, Inc.
4694.TJPXHealthcareMedical - Diagnostics & Research
Latest quote
¥3,635
+¥10.00 · +0.28%
4694.T company overview
Regular session · JST · Market data may be delayed.
Company profile
Company websiteBML, Inc. is a Japanese corporation specializing in a comprehensive range of laboratory diagnostics and related services. The company conducts standard analyses such as biochemical and hematological screenings, in addition to advanced specialized tests including radioimmunoassay (RIA), cellular diagnostics, immunology, and DNA analysis. It also provides microbiological assessments for medical and pharmaceutical organizations, along with diagnostic services covering critical areas like oncology, infectious diseases, metabolic disorders (diabetes, hypertension), allergies, and genetic studies. To optimize laboratory operations, BML develops proprietary automation systems, Frontier and Symphony, designed to streamline processes from initial sample sorting and dispensing through to subsequent testing. The firm also supports medical information networking via electronic health records and offers preventative healthcare solutions. BML's extensive service portfolio includes food safety and environmental health. Its food division provides comprehensive hygiene control and processing support, encompassing contractual microbiological testing for raw ingredients, prepared, and processed foods. This extends to environmental hygiene assessments for food facilities and kitchens, general microorganism testing, and the evaluation of genetically modified organisms. Environmental services comprise drinking water and wastewater analysis, occupational health management (measuring airborne substances like ethylene oxide, formaldehyde, organic solvents, and dust), comprehensive indoor environmental monitoring (identifying contaminants and other variables), and biological dioxin surveillance. Moreover, BML performs analyses for residual agricultural chemicals, offers dental diagnostics for caries and periodontal diseases, provides consulting for pharmaceutical product approvals, conducts investigative analyses for drug manufacturers, and performs gene expression analysis, specifically identifying genes linked to infectious disease susceptibility. Founded in 1955, BML, Inc. is headquartered in Tokyo, Japan.
- Industry
- Medical - Diagnostics & Research
- Sector
- Healthcare
- Headquarters
- JP
- CEO
- Kensuke Kondo
- Listed since
- Apr 25, 2001
- Employees
- 4,612
Market position
- Volume
- 53.2K
- 0.67× average
- Average volume
- 79.45K
- Average daily volume
- Market cap
- 136.25B JPY
- Beta
- 0.24
- Market reference 1
Financials
Financial snapshot
Latest / TTMValuation & yield
- P/E (TTM)
- 17.4×
- P/B (TTM)
- 1.07×
- P/S (TTM)
- 0.9×
- Dividend yield
- 3.44%
Profitability & efficiency
- Gross margin
- 32.57%
- Operating margin
- 7.02%
- Net margin
- 5.20%
Financial health
- Debt / equity
- 0.04×
- Altman Z-score
- 4.03
- Piotroski F-score
- 5 of 9
Financial statements
Margin trends
Profitability as a percentage of reported revenue.
Income trends
Revenue
Operating income
Net income
| Metric (JPY) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 150.26B JPY | 143.19B JPY | 137.96B JPY | 159.46B JPY | 186.07B JPY |
| Cost of goods sold | 101.57B JPY | 97.33B JPY | 92.34B JPY | 98.02B JPY | 99.12B JPY |
| Gross profit | 48.69B JPY | 45.86B JPY | 45.63B JPY | 61.45B JPY | 86.95B JPY |
| Research and development | — | 260M JPY | 275M JPY | 271M JPY | 302M JPY |
| Selling, general, and administrative | 38.27B JPY | 36.24B JPY | 36.19B JPY | 37.24B JPY | 37.76B JPY |
| Operating expenses | 38.27B JPY | 36.5B JPY | 36.46B JPY | 37.51B JPY | 38.06B JPY |
| Interest income | 106M JPY | — | — | — | — |
| Interest expense | 119M JPY | 118M JPY | 104M JPY | 40M JPY | 36M JPY |
| Depreciation and amortization | 9.12B JPY | 7.72B JPY | 6.79B JPY | 6.35B JPY | 5.89B JPY |
| Operating income | 10.42B JPY | 9.37B JPY | 9.17B JPY | 23.94B JPY | 48.89B JPY |
| Net income | 7.75B JPY | 6.26B JPY | 6.04B JPY | 15.58B JPY | 33.74B JPY |
Company facts updated Aug 24, 2026.
Earnings
- EPS beat rate
- 0%
- 0 beats, 1 miss, 0 met estimates
- Average EPS surprise
- -15.64%
- 1 comparable report
- Latest EPS result
- 52.85
EPS: actual versus estimate
Recent quarterly results
Revenue: actual versus estimate
Recent quarterly results
Corporate actions
Corporate action history
| Action | Effective date | Details | Record date | Payment date |
|---|---|---|---|---|
Stock split | Aug 29, 2016 | 2:1 | — | — |
Effective Aug 29, 2016
2:1
4694.T peers
ETFs holding 4694.T
Funds reporting this stock among their holdings, ordered by reported position size.
iShares Core TOPIX ETF1475.T256.65M0.01%2.89T JPY0.05%¥417.7-0.07%
Vanguard Total International Stock ETFVXUS6.81M0.00%646.2B USD0.05%$87.71+0.78%
Avantis International Small Cap Value ETFAVDV5.05M0.03%20.24B USD0.36%$111.95+1.06%
Vanguard FTSE Developed Markets ETFVEA4.39M0.00%315B USD0.03%$73.42+0.80%
iShares Core MSCI EAFE ETFIEFA3M0.00%195.14B USD0.07%$100.85+0.86%
Vanguard FTSE All-World ex-US Small-Cap ETFVSS1.67M0.01%13.6B USD0.06%$160.06+0.43%
iShares MSCI EAFE Small-Cap ETFSCZ1.51M0.01%13.28B USD0.40%$86.60+0.70%
iShares Core MSCI Total International Stock ETFIXUS1.35M0.00%60.91B USD0.07%$97.945+0.76%
iShares Core TOPIX ETF1475.T- Market value
- 256.65M
- Weight
- 0.01%
- AUM
- 2.89T JPY
- Expense ratio
- 0.05%
- Price / 1D
- ¥417.7-0.07%
Vanguard Total International Stock ETFVXUS- Market value
- 6.81M
- Weight
- 0.00%
- AUM
- 646.2B USD
- Expense ratio
- 0.05%
- Price / 1D
- $87.71+0.78%
Avantis International Small Cap Value ETFAVDV- Market value
- 5.05M
- Weight
- 0.03%
- AUM
- 20.24B USD
- Expense ratio
- 0.36%
- Price / 1D
- $111.95+1.06%
Vanguard FTSE Developed Markets ETFVEA- Market value
- 4.39M
- Weight
- 0.00%
- AUM
- 315B USD
- Expense ratio
- 0.03%
- Price / 1D
- $73.42+0.80%
iShares Core MSCI EAFE ETFIEFA- Market value
- 3M
- Weight
- 0.00%
- AUM
- 195.14B USD
- Expense ratio
- 0.07%
- Price / 1D
- $100.85+0.86%
Vanguard FTSE All-World ex-US Small-Cap ETFVSS- Market value
- 1.67M
- Weight
- 0.01%
- AUM
- 13.6B USD
- Expense ratio
- 0.06%
- Price / 1D
- $160.06+0.43%
iShares MSCI EAFE Small-Cap ETFSCZ- Market value
- 1.51M
- Weight
- 0.01%
- AUM
- 13.28B USD
- Expense ratio
- 0.40%
- Price / 1D
- $86.60+0.70%
iShares Core MSCI Total International Stock ETFIXUS- Market value
- 1.35M
- Weight
- 0.00%
- AUM
- 60.91B USD
- Expense ratio
- 0.07%
- Price / 1D
- $97.945+0.76%
Continue in GoAI
Research 4694.Tresearch.disclaimer





